RSS

UCB

In this online exclusive, Erik Janssen, vice president of Global New Patient Solutions Neurology at UCB, talks about why advancements in big data and analytics might be the key to helping patients with epilepsy. more

Opinion

Pharmaceutical firm UCB Manufacturing Ireland have gained massive profits, chiefly arisen from the sale of the IP of its Parkinson’s disease drug. more

News

UCB’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS) in adults with epilepsy and is now available on the NHS more

News

Pfizer, AstraZeneca, Merck and other Big Pharma companies have signed up to a consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s more

News

Biopharma group UCB’s newly appointed Chief Executive Officer, Jean-Christophe Tellier, is already making waves in the industry, having been selected to join the Ministerial Industry Strategy Group (MISG). more

News

Participating companies are AstraZeneca, GSK, Janssen R&D, Lilly, Pfizer, Takeda and UCB. more